Showing 1501-1510 of 2050 results for "".
- Injectsense and Injectpower Secure $9.4M to Support Injectsense's First-in-Human Studies for Sensors that Continuously Measure IOPhttps://modernod.com/news/injectsense-and-injectpower-secure-94m-to-support-injectsenses-first-in-human-studies-for-sensors-that-continuously-measure-iop/2481973/Injectsense and sister company Injectpower, a developer of ultra-miniature solid-state microbatteries for medical applications, announced combined funding of $9.4 million to bring highly integrated autonomous implantable devices—smaller than a grai
- Tilak Healthcare Raises €10 Million to Continue Growing Its Ophthalmological Telemedicine Offeringhttps://modernod.com/news/tilak-healthcare-raises-eur10-million-to-continue-growing-its-leading-ophthalmological-telemedicine-offering/2481890/Tilak Healthcare has raised €10 million in a funding to accelerate the roll-out of OdySight in France and abroad, and to develop new solutions for other medical conditions. OdySight is the first remote monitoring system for ophthalmic conditions combined with a gaming interface designed
- Johnson & Johnson Vision Presents Data at #Academy23 on ACUVUE MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-presents-data-at-academy23-on-acuvue-max-1-day-contact-lenses/2481885/Johnson & Johnson Vision will present data on the ACUVUE OASYS MAX 1-Day brand family of lenses and research on myopia progression, along with learning opportunities and support of Sight for Kids at the Academy 2023 New Orleans meeting, October 11–14. In celebration
- SightGlass Vision Presents New Data on Diffusion Optics Technology Myopia Controlhttps://modernod.com/news/sightglass-vision-presents-new-data-on-diffusion-optics-technology-myopia-control/2481876/Findings from three
- Resolving a Seeming Contradiction, Study Advances Understanding of Visual Recognition Memoryhttps://modernod.com/news/resolving-a-seeming-contradiction-study-advances-understanding-of-visual-recognition-memory/2481866/Researchers from The Picower Institute for Learning and Memory have published a study evaluating how our vision is so good at recognizing what’s familiar. The study, published in the Journa
- New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgeryhttps://modernod.com/news/new-trefoil-therapeutics-data-presented-at-arvo-demonstrate-that-tthx1114-controls-edema-in-at-risk-patients-undergoing-cataract-surgery/2481556/Trefoil Therapeutics announced a series of data presentations demonstrating the potential use of TTHX1114 to protect endothelial cells at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The company also announced the completion of the phase 1 epithel
- SightGlass Vision: Research Reinforces Myopia Control Efficacy and Safety of Diffusion Optics Technology Spectacle Lenseshttps://modernod.com/news/sightglass-vision-research-reinforces-myopia-control-efficacy-and-safety-of-diffusion-optics-technology-spectacle-lenses/2481552/SightGlass Vision announced positive outcomes of multiple studies designed to evaluate the performance of its Diffusion Optics Technology spectacle lenses, which are designed to slow the progression of myopia in children. All are being presented this week at the 2023 ARVO Annual Me
- CDC: Cases of Vision Loss and Death Due to Drug-Resistant Bacteria Linked to Artificial Tears Continues to Risehttps://modernod.com/news/cdc-cases-of-vision-loss-and-death-due-to-drug-resistant-bacteria-linked-to-artificial-tears-continues-to-rise/2481488/Federal officials say three people have died as part of a growing number of cases of infections from a rare, extensively drug-resistant strain of Pseudomonas aeruginosa found in some artificial tears. There have also been 8 reports of vision loss and 4 reports of enucleatio
- Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in DME Following Interim Analysishttps://modernod.com/news/oxurion-announces-the-continuation-of-kalahari-phase-2-part-b-study-in-dme-following-interim-analysis/2481293/Oxurion NV announced that an Independent Data Monitoring Committee (IDMC) completed its planned interim analysis of the KALAHARI phase 2, Part B clinical trial evaluating Oxurion’s novel plasma kallikrein (PKal) candidate, THR
- Alcon to Celebrate 75 Years and Showcase Contact Lens Innovations at #Academy22https://modernod.com/news/alcon-to-celebrate-75-years-and-showcase-contact-lens-innovations-at-academy22/2481197/Alcon will feature a host of innovations across its portfolio of products along with pertinent practice takeaways at the American Academy of Optometry Annual Meeting (#Academy22) in San Diego, California, on October 27, 2022. The meeting coincides with Alcon’s Diamond Jubilee, celebrating 7